Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Susanne Nährig"'
Autor:
Sivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, Florian Stehling, Folke Brinkmann, Manuel Burkhart, Helmut Ellemunter, Anna-Maria Dittrich, Christina Smaczny, Olaf Eickmeier, Matthias Kappler, Carsten Schwarz, Sarah Sieber, Susanne Naehrig, Lutz Naehrlich, Klaus Tenbrock, Claus Pfannenstiel, Dirk Steffen, Jochen Meister, Britta Welzenbach, Anette Scharschinger, Markus Kratz, Maike Pincus, Tobias Tenenbaum, Mirjam Stahl, Kerstin Landwehr, Stefanie Dillenhöfer, Hans Kössel, Petra Kaiser, Manfred Käding, Simone Stolz, Stefan Blaas, Jutta Hammermann, Monika Gappa, Antje Schuster, Dana Spittel, Sabine Zirlik, Sabina Schmitt, Joachim Bargon, Malte Cremer, Sebastian Fähndrich, Andrea Heinzmann, Lutz Nährlich, Stefan Kuhnert, Sebastian Schmidt, Bettina Wollschläger, Anna Nolde, Inka Held, Wolfgang Kamin, Felix C. Ringshausen, Sabine Wege, Olaf Sommerburg, Norbert Geier, Sara Lisa Fleser, Heinrike Wilkens, Michael Lorenz, Paul Vöhringer, Martin Schebek, Christian Timke, Ingrid Bobis, Thomas Nüßlein, Doris Dieninghoff, Ernst Rietschel, Bastian Klinkhammer, Freerk Prenzel, Alexandra Wald, Axel Kempa, Eva Lücke, Ines Adams, Krystyna Poplawska, Simone Lehmkühler, Monika Bauck, Anne Pfülb, Rainald Fischer, Gudrun Schopper, Susanne Nährig, Matthias Griese, Jörg Grosse, Peter Küster, Birte KinderHolger Köster, Susanne Büsing, Margarethe Pohl, Andreas Artlich, Alexander Kiefer, Manfred Ballmann, Nikola Gjorgjevski, Markus A. Rose, Friederike Ruf, Rolf Mahlberg, Wolfgang Thomas, Ute Graepler, Sebastian Bode, hilipp Meyn, Josef Rosenecker, Cordula Koerner, Klaus-Michael Keller, Tina Teßmer, Helge Hebestreit, Gerhild Lohse
Publikováno v:
The Lancet Regional Health. Europe, Vol 32, Iss , Pp 100690- (2023)
Summary: Background: Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study evaluated the real-world impact of ETI on lung function,
Externí odkaz:
https://doaj.org/article/cb7f1132ad9145b4909f1a838def4b95
Autor:
Silke van Koningsbruggen-Rietschel, Jane C. Davies, Tacjana Pressler, Rainald Fischer, Gordon MacGregor, Scott H. Donaldson, Knut Smerud, Nils Meland, Jann Mortensen, Marie Ø. Fosbøl, Damian G. Downey, Astrid H. Myrset, Hugo Flaten, Philip D. Rye, The following investigators and their teams (in alphabetical order) conducted this study., Mary Carroll, Jane Davies, Carsten Schwarz, Nico Derichs, Damian Downey, Olaf Eickmeier, Pal Leyell Finstad, Marie Øbro Fossbøl, Marita Gilljam, Lena Hjelte, Alan Knox, Susanne Nährig, Joachim Riethmüller, Felix C. Ringshausen, AS AlgiPharma, Laura Gow, Joy Conway, William Bennett
Publikováno v:
ERJ Open Research, Vol 6, Iss 4 (2020)
Background OligoG is a low molecular-weight alginate oligosaccharide that improves the viscoelastic properties of cystic fibrosis (CF) mucus and disrupts biofilms, thereby potentiating the activity of antimicrobial agents. The efficacy of inhaled Oli
Externí odkaz:
https://doaj.org/article/bf6a51f4c4a3405ebe8677a3a47a674d
Autor:
Anne-Sophie Kalla, Michael Vogeser, Susanne Nährig, Mathias Bruegel, Katharina Habler, Michael Paal, Daniel Teupser, Michael Rychlik
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 60:82-91
Objectives Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators have revolutionized the therapeutic landscape in CF treatment. These vital drugs are extensively metabolized via CYP3A, so caution must be exercised in multimodal C
Autor:
Kathrin Kahnert, Diego Kauffmann-Guerrero, Pontus Mertsch, Susanne Nährig, Dennis Nowak, Uta Ochmann, Florian Steiner, Zulfiya Syunyaeva, Amanda Tufman
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cbefd7a9c43c92987596878dd3abb2a
https://doi.org/10.1016/b978-3-437-23337-1.00007-2
https://doi.org/10.1016/b978-3-437-23337-1.00007-2
Autor:
Stefan Endres, Claudia Dechant, Michael Drey, Ulrich Hoffmann, Kathrin Kahnert, Diego Kauffmann-Guerrero, Volker Klauss, Andreas König, Pontus Mertsch, Susanne Nährig, Dennis Nowak, Uta Ochmann, Fuat S. Oduncu, Felix Röpcke, Harald Rupprecht, Stefan Schewe, Ralf Schmidmaier, Florian Steiner, Zulfiya Syunyaeva, Federico Tatò, Amanda Tufman, Andreas Völkl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25c21905f17c1dded6f6f2761f3ef98f
https://doi.org/10.1016/b978-3-437-23337-1.09988-4
https://doi.org/10.1016/b978-3-437-23337-1.09988-4
Autor:
Julia Ley-Zaporozhan, Gregor Dückers, Ellen D. Renner, Carolin Kröner, Jens Neumann, Susanne Nährig, Bernd H. Belohradsky, Iris Meixner, Benedikt D. Spielberger, Matthias Griese, Matthias Kappler, Simone Reu, Beate Hagl, Joseph Rosenecker, Michael Borte, Tim Niehues
Publikováno v:
Allergy. 74:1691-1702
Background Pulmonary complications are responsible for high morbidity and mortality rates in patients with the rare immunodeficiency disorder STAT3 hyper-IgE syndrome (STAT3-HIES). The aim of this study was to expand knowledge about lung disease in S
Autor:
Claudia Dechant, Michael Drey, Stefan Endres, Ulrich Hoffmann, Kathrin Kahnert, Diego Kauffmann-Guerrero, Volker Klauss, Andreas König, Pontus Mertsch, Susanne Nährig, Dennis Nowak, Uta Ochmann, Fuat S. Oduncu, Felix Röpcke, Harald Rupprecht, Stefan Schewe, Ralf Schmidmaier, Zulfiya Syunyaeva, Federico Tatò, Amanda Tufman, Andreas Völkl, Martin Fischer, Rudolf Maria Huber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ca7ce8c663111a5b54d743c139cde53
https://doi.org/10.1016/b978-3-437-23336-4.01002-9
https://doi.org/10.1016/b978-3-437-23336-4.01002-9
Autor:
Amanda Tufman, Kathrin Kahnert, Diego Kauffmann-Guerrero, Pontus Mertsch, Zulfiya Syunyaeva, Uta Ochmann, Dennis Nowak, Susanne Nährig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30be69cc6c25ef8003235f4ef2d08f2f
https://doi.org/10.1016/b978-3-437-23336-4.00007-1
https://doi.org/10.1016/b978-3-437-23336-4.00007-1
Publikováno v:
Der Internist. 50:1213-1220
During the last 30 years, life expectancy in patients with cystic fibrosis has significantly improved. In Germany, almost half of the 8500 patients are 18 years or older. Older patients have increased rates of cystic fibrosis typical complications, I